Bio-Path Holdings Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$12.03 |
Market Cap |
$38.22 M |
Shares Outstanding |
2.83 M |
Public Float |
1.72 M |
Address |
4710 Bellaire Boulevard Bellaire Texas 77401 United States |
Employees | - |
Website | http://www.biopathholdings.com |
Updated | 07/08/2019 |
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company utilizing a novel technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its platform DNAbilize, uses P-ethoxy, which is a deoxyribonucleic acid backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a neutral charged lipid bilayer. The company was founded by Peter Nielsen, Douglas P. |